Current partner codePEPTIDESDE
NCT05295875·Phase 2·INTERVENTIONAL

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Status

Completed

Phase

Phase 2

Enrollment

391

Locations

31

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.

Interventions

Treatment arms and agents.

DRUG

ALT-801

Injected subcutaneously (SC)

OTHER

Placebo

Injected subcutaneously (SC)

Timeline

From registration to results.

  1. First posted

    Mar 25, 2022

  2. Study start

    Mar 31, 2022

  3. Primary completion

    Sep 28, 2023

  4. Study completion

    Sep 28, 2023

  5. Results posted

    Not reported

  6. Registry updated

    Nov 29, 2023

Outcomes

What the study measures.

Primary outcomes

Relative change from baseline in body weight percentage

Time frame · Baseline to Week 48

Secondary outcomes

Percent proportion of subjects with weight loss of greater than or equal to 5%, 10%, and 15%

Time frame · Baseline to Week 48

Change from baseline in lipids

Time frame · Baseline to Week 48

The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)

Time frame · Baseline to Week 48

Changes from baseline in Fasting Glucose

Time frame · Baseline to Week 48

Changes from baseline in Hemoglobin A1c

Time frame · Baseline to Week 48

Changes from baseline in Homeostatic Marker Assessment for Insulin Resistance (HOMA-IR)

Time frame · Baseline to Week 48

Changes from baseline in: a) Systolic blood pressure, b) Diastolic blood pressure

Time frame · Baseline to Week 48

Change from baseline in proportion of patients using antihypertensive medications

Time frame · Baseline to Week 48

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
75 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Written informed consent signed prior to entry into the study * Male or female age 18 to 75 years, inclusive * Body mass index (BMI) ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 combined with at least one obesity-related comorbidity * At least one unsuccessful weight loss attempt per investigator judgement * Agreement to comply with the study-required life-style intervention and treatment during the full duration of the study * Female subjects of childbearing potential who are not pregnant or breastfeeding, do not plan to become pregnant during the study, and agree to use effective birth control Exclusion Criteria: * Weight gain or loss \> 5% in the 3 months prior to randomization or \>10% in the 6 months prior to screening * Diabetes and related conditions: 1. History or clinical evidence of diabetes mellitus of any type, including Type 1, Type 2, or mature onset diabetes of the young (MODY) 2. HbA1c \> 6.5%, fasting glucose ≥ 126 mg/dL (6.9 mmol/L), and/or random glucose of ≥ 200 mg/dL (11.0mmol/L) at screening * Obesity and related conditions: 1. Obesity induced by known genetic causes or endocrine disorders (eg, Cushing Syndrome, inadequately treated hypothyroidism, defined as thyroid-stimulating hormone \[TSH\] \> 6 mIU/L) 2. History of bariatric surgery or other surgical treatment for obesity (eg, gastric banding, gastric bypass), or planned surgery or surgical treatment during the study. Liposuction and/or abdominoplasty performed \>1 year before screening is allowed. Endoscopically placed intragastric balloons will be allowed if removed \> 1 year before screening. * Gastrointestinal conditions: 1. History of acute or chronic pancreatitis within 1 year (365 days) before screening 2. History of or acute significant gastrointestinal (GI) disorder (eg, peptic ulcers, severe gastroesophageal reflux disease \[GERD\], 3. History of GI surgery, including cholecystectomy and antrectomy. Surgery for appendicitis and small bowel resection \>20cm is acceptable. 4. History of inflammatory bowel disease, celiac disease or any medical condition or surgery that could affect gastric emptying, stool frequency or stool consistency. (Irritable bowel syndrome is permitted provided that bowel frequency and consistency are normal off treatment.) * Mental health conditions: 1. Untreated depressive disorder, defined as a Patient Health Questionaire-9 (PHQ-9) score of ≥ 15 at screening 2. Suicide ideation, defined as type 4 or 5 on the Columbia-Suicide Severity Rating Scale(C-SSRS) at screening, lifelong history of a suicide attempt, or suicidal behavior within 30 days before screening 3. Other severe psychiatric disorder (eg, schizophrenia, bipolar disorder)

Study locations

31 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

Altimmune CTM

Birmingham, Alabama, United States

Altimmune CTM

Mesa, Arizona, United States

Altimmune CTM

Los Angeles, California, United States

National Research Institute

Los Angeles, California, United States

Altimmune CTM

Montclair, California, United States

Altimmune CTM

Santa Barbara, California, United States

Altimmune CTM

Boca Raton, Florida, United States

Altimmune CTM

Clearwater, Florida, United States

Altimmune CTM

Fort Myers, Florida, United States

Altimmune CTM

Jacksonville, Florida, United States

Altimmune CTM

Port Orange, Florida, United States

Altimmune CTM

Sunrise, Florida, United States

Altimmune CTM

Savannah, Georgia, United States

Altimmune CTM

Evanston, Illinois, United States

Altimmune CTM

Indianapolis, Indiana, United States

Midwest Institute for Clinical Research

Indianapolis, Indiana, United States

Altimmune CTM

Louisville, Kentucky, United States

Altimmune CTM

Baton Rouge, Louisiana, United States

Altimmune CTM

New Orleans, Louisiana, United States

Altimmune CTM

Kansas City, Missouri, United States

Altimmune CTM

Butte, Montana, United States

Altimmune CTM

Berlin, New Jersey, United States

Altimmune CTM

New York, New York, United States

Cornell University, Joan and Sanford Weill Medical College

New York, New York, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Pemvidutide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.